...
首页> 外文期刊>Bone marrow transplantation >Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression
【24h】

Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression

机译:成年再生障碍性贫血患者中没有HLA的同胞且免疫抑制失败的成年再生障碍性贫血患者的无关供体搜索和无关供体移植

获取原文
获取原文并翻译 | 示例
           

摘要

Currently at least 75% of patients with severe aplastic anaemia can be successfully transplanted using a matched unrelated donor (UD) haematopoietic SCT (HSCT). For children, outcomes are similar to matched sibling donor (MSD) HSCT. This improvement in outcome over time is likely due to improved HLA tissue typing to identify better matched donors, improvements in the conditioning regimen, particularly fludarabine-based regimens, and improved supportive care. Graft rejection occurs in ~15% of adults, but is less frequent in children. Chronic GVHD remains a concern but may be reduced by using Alemtuzumab instead of ATG. UD HSCT should be considered early after failure to respond to one course of immunosuppressive therapy, but for children who lack a MSD up front matched UD HSCT may be considered.
机译:目前,至少有75%的再生障碍性贫血患者可以使用匹配的无关供体(UD)造血SCT(HSCT)成功移植。对于儿童,结局与配对的同胞供者(MSD)HSCT相似。随着时间的流逝,结果的改善可能是由于改善HLA组织类型以更好地识别匹配的供体,改善了治疗方案,特别是基于氟达拉滨的治疗方案,以及改善了支持治疗。嫁接排斥发生在约15%的成年人中,但在儿童中发生频率较低。慢性GVHD仍然值得关注,但可以通过使用Alemtuzumab代替ATG来降低。在对一个疗程的免疫抑制疗法无效后应尽早考虑UD HSCT,但是对于缺少MSD的儿童,可以考虑预先匹配的UD HSCT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号